Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2019-08-12 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
USFDA COMPLETES INSPECTION OF NATCO's MEKAGUDA ACTIVE PHARMACEUTICAL INGREDIENT FACILITY
Regulatory Filings
2019-08-12 English
Book Closure from 3rd September 2019 to 5th September 2019
Regulatory Filings
2019-08-09 English
AGM/Book Closure
AGM Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges informing them about the scheduling of the 36th Annual General Meeting (AGM) for the financial year 2018-19. It includes the date, time, venue, and book closure dates for the AGM. There is no financial data, report content, or detailed presentation included. The document serves as an announcement or intimation about the AGM event itself, not the AGM materials or report. Therefore, it fits the category of AGM Information (AGM-R). The document length is short and focused solely on the AGM notification, confirming this classification.
2019-08-09 English
36th Annual Report for the year 2018-19
Regulatory Filings
2019-08-09 English
Outcome of Board Meeting
Regulatory Filings
2019-08-09 English
Record Date
Regulatory Filings Classification · 95% confidence The document is a formal communication dated 9th August 2019 from NATCO Pharma Limited to stock exchanges regarding the outcome of a Board Meeting. It announces the approval of unaudited financial results for the quarter ended 30th June 2019, declaration of an interim dividend, and approval of investments. The document includes no detailed financial statements or substantive financial data itself but refers to the unaudited financial results and a limited review report being enclosed. The document is relatively short (2458 characters) and serves as an announcement of the board meeting outcomes rather than the full interim report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about financial results and dividend declaration, not the full interim/quarterly report itself.
2019-08-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.